---
layout: post
title: "Amylyx Pharmaceuticals, Inc.; Withdrawal of Approval of New Drug Application for RELYVRIO (Sodium Phenylbutyrate and Taurursodiol) for Suspension, 3 Gram/Packet and 1 Gram/Packet"
date: 2026-02-04 21:49:11 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-16646
original_published: 2025-08-29 00:00:00 +0000
significance: 8.00
---

# Amylyx Pharmaceuticals, Inc.; Withdrawal of Approval of New Drug Application for RELYVRIO (Sodium Phenylbutyrate and Taurursodiol) for Suspension, 3 Gram/Packet and 1 Gram/Packet

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** August 29, 2025 00:00 UTC
**Document Number:** 2025-16646

## Summary

The Food and Drug Administration (FDA or Agency) is withdrawing approval of the new drug application (NDA) for RELYVRIO (sodium phenylbutyrate and taurursodiol) for suspension, 3 gram (g)/ packet and 1 g/packet, held by Amylyx Pharmaceuticals, Inc. (Amylyx), 43 Thorndike St., Cambridge, MA 02141. Amylyx has voluntarily requested that FDA withdraw approval of this application and has waived its opportunity for a hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/08/29/2025-16646/amylyx-pharmaceuticals-inc-withdrawal-of-approval-of-new-drug-application-for-relyvrio-sodium)
- API: https://www.federalregister.gov/api/v1/documents/2025-16646

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
